Nobuya Abe

Nobuya Abe

Auto-generated profile, based on publicly available information

Nobuya Abe

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
NANobuya Abe
Nobuya Abe
MTMasato Tarumi
Masato Tarumi
YFYuichiro Fujieda
Yuichiro Fujieda
NTNobuhiko Takahashi
Nobuhiko Takahashi
KKKohei Karino
Kohei Karino
MMMasaaki Murakami
Masaaki Murakami
Objectives The central nervous system disorder in systemic lupus erythematosus (SLE), called neuropsychiatric lupus (NPSLE), is one of the most severe phenotypes with various clinical symptoms, including mood disorder, psychosis and delirium as diffuse neuropsychological manifestations (dNPSLE). Although stress is one of the aggravating factors for neuropsychiatric symptoms, its role in the pathogenesis of dNPSLE remains to be elucidated. We aimed to investigate stress effects on the neuropsychiatric pathophysiology in SLE using lupus-prone mice and patients’ data. Methods Sleep disturbance stress (SDS) for 2 weeks was placed on 6–8-week-old female MRL/lpr and control mice. Behavioural phenotyping, histopathological analyses and gene and protein expression analyses were performed to assess SDS-induced neuroimmunological alterations. We also evaluated cytokines of the cerebrospinal fluid and brain regional volumes in patients with dNPSLE and patients with non-dNPSLE. Results SDS-subjected MRL/lpr mice exhibited less anxiety-like behaviour, whereas stressed control mice showed increased anxiety. Furthermore, stress strongly activated the medial prefrontal cortex (mPFC) in SDS-subjected MRL/lpr. A transcriptome analysis of the PFC revealed the upregulation of microglial activation-related genes, including Il12b. We confirmed that stress-induced microglial activation and the upregulation of interleukin (IL) 12/23p40 proteins and increased dendritic spines in the mPFC of stressed MRL/lpr mice. IL-12/23p40 neutralisation and tyrosine kinase 2 inhibition mitigated the stress-induced neuropsychiatric phenotypes of MRL/lpr mice. We also found a higher level of cerebrospinal fluid IL-12/23p40 and more atrophy in the mPFC of patients with dNPSLE than those with non-dNPSLE. Conclusions The microglial IL-12/23 axis in the mPFC might be associated with the pathogenesis and a promising therapeutic target for dNPSLE.

21 October 2019 in Lupus
Verified
Journal Article
Closed access
PDF file
TST Sato
T Sato
HNH Nakamura
H Nakamura
YFY Fujieda
Y Fujieda
NON Ohnishi
N Ohnishi
NAN Abe
N Abe
TAT Atsumi
T Atsumi
The objective of this study was to clarify the efficacy and safety of factor Xa inhibitors for antiphospholipid syndrome patients in real world utilization. This is a retrospective cohort study comprised of all consecutive patients with antiphospholipid syndrome in our department over a period of 28 years. Patients treated with factor Xa inhibitors were extracted from the cohort. As a control group, patients treated with warfarin were selected from the same cohort with matched age, gender, coexistence of systemic lupus erythematosus, and the presence of antiplatelet therapy, after which we used a propensity score for each of the risk factors as an additional covariate in multivariate Cox proportional hazard regression. The primary endpoint was set as thrombotic and hemorrhagic event-free survival for five years. Among 206 patients with antiphospholipid syndrome, 18 had a history of anti-Xa therapy (five rivaroxaban, 12 edoxaban, one apixaban). Fourteen out of 18 patients on anti-Xa therapy had switched to factor Xa inhibitors from warfarin. Event-free survival was significantly shorter during anti-Xa therapy than that during warfarin therapy (hazard ratio: 12.1, 95% confidence interval: 1.73–248, p = 0.01) ( Figure 1(a) ). Similarly, event-free survival in patients treated with factor Xa inhibitors was significantly shorter compared with controls (hazard ratio: 4.62, 95% confidence interval: 1.54–13.6, p = 0.0075). In the multivariate Cox proportional hazard model, event-free survival in patients with anti-Xa therapy remained significantly shorter (hazard ratio: 11.9, 95% confidence interval: 2.93–56.0, p = 0.0005). Factor Xa inhibitors may not be recommended for antiphospholipid syndrome.

24 January 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
KKKohei Karino
Kohei Karino
MKMichihito Kono
Michihito Kono
STShuhei Takeyama
Shuhei Takeyama
YKYuki Kudo
Yuki Kudo
MKMasatoshi Kanda
Masatoshi Kanda
TATatsuya Atsumi
Tatsuya Atsumi

25 November 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
TKTakashi Kudo
Takashi Kudo
DNDaigo Nakazawa
Daigo Nakazawa
KWKanako Watanabe-Kusunoki
Kanako Watanabe-Kusunoki
MKMasatoshi Kanda
Masatoshi Kanda
SSSatoka Shiratori‐Aso
Satoka Shiratori‐Aso
TATatsuya Atsumi
Tatsuya Atsumi

31 March 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
ASAtsushi Sanada
Atsushi Sanada
NANobuya Abe
Nobuya Abe
MBMiyuki Bohgaki
Miyuki Bohgaki
HKHideki Kasahara
Hideki Kasahara
Atsushi Sanada, Nobuya Abe, Miyuki Bohgaki, Hideki Kasahara; Therapeutic effectiveness of upadacitinib combined with glucocorticoid on remission induction and m

15 March 2022 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
NANobuya Abe
Nobuya Abe
YFYuichiro Fujieda
Yuichiro Fujieda
KTKhin K. Tha
Khin K. Tha
HNHisashi Narita
Hisashi Narita
KAKuniyuki Aso
Kuniyuki Aso
TATatsuya Atsumi
Tatsuya Atsumi